Xceleron Inc. is a technology company.
Xceleron Inc. has raised $10.0M across 3 funding rounds.
Xceleron Inc. has raised $10.0M in total across 3 funding rounds.
Xceleron Inc. has raised $10.0M in total across 3 funding rounds.
Xceleron Inc.'s investors include Albion VC.
Xceleron Inc. is a specialized contract research organization (CRO) based in Germantown, Maryland, that pioneered the use of 14C microtracers and Accelerator Mass Spectrometry (AMS) technology to accelerate early-stage pharmaceutical R&D.[1][2][3] The company, founded in 1998, designs preclinical and clinical investigations leveraging AMS's unique sensitivity for detecting ultra-low levels of compounds, outperforming traditional methods like LC-MS/MS and Liquid Scintillation Counting, with reported revenue around $15 million and fewer than 25 employees.[1][2]
Xceleron serves pharmaceutical companies by solving challenges in drug metabolism, bioavailability, and human disposition studies, enabling more efficient R&D through microdosing and precise analytics.[1][5] It has influenced industry adoption of AMS as a standard tool, though no recent news indicates current growth momentum, and records note a Chapter 11 filing, suggesting past financial challenges.[3]
Xceleron Inc. was established in 1998 in Germantown, Maryland, as a pioneer in applying 14C microtracers and AMS analytical technology to pharmaceutical research and development.[1][2] The founders recognized AMS's potential for robust detection at extremely low levels, leading to proprietary methods that redesigned preclinical and clinical studies for greater efficiency.[1]
Early traction came from increased industry adoption, positioning AMS as a valuable alternative to conventional platforms and establishing Xceleron's role in advancing drug development tools.[1] Specific founder details are unavailable in available records, but the company's focus evolved around specialized CRO services for early-stage drug acceleration.[3][5]
Xceleron rides the trend of precision analytics in pharmaceutical R&D, where AMS enables microdosing to reduce costs and risks in early drug testing amid rising development expenses.[1][3] Timing was ideal post-1998, as regulatory acceptance of sensitive detection methods grew, favoring market forces like demand for faster, safer drug pipelines.[1]
The company influenced the ecosystem by popularizing AMS, shifting industry standards toward more efficient tools and impacting CRO competitiveness in biotech.[1][2] However, its Chapter 11 status highlights vulnerabilities in niche CROs to consolidation and funding pressures in pharma services.[3]
Xceleron's legacy in AMS innovation positions any revival or successor to capitalize on AI-enhanced analytics and personalized medicine trends, potentially expanding microdosing applications in biologics and gene therapies. Evolving influence may involve acquisition by larger CROs, amplifying its tech in global R&D. Watch for partnerships riding efficiency demands in a post-Chapter 11 landscape, tying back to its foundational role in redefining pharmaceutical precision.[1][3]
Xceleron Inc. has raised $10.0M across 3 funding rounds. Most recently, it raised $2.0M Venture Round in February 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2012 | $2.0M Venture Round | Albion VC | |
| Dec 1, 2006 | $4.0M Series B | Albion VC | |
| May 1, 2005 | $4.0M Venture Round | Albion VC |